‍FVR appoints Jenni Vuola as CEO

Jenni Vuola has been appointed Chief Executive Officer of FVR – Finnish Vaccine Research and will assume the role in April 2026.

‍

Vuola holds a PhD in microbiology and is an Adjunct Professor (Docent) in infectious disease research. She began her career in academic vaccine development research, spending ten years at the former National Public Health Institute (now the Finnish Institute for Health and Welfare, THL), followed by a postdoctoral period at the University of Oxford.

‍

She spent the following twenty years in the international pharmaceutical industry, working for GSK, Sanofi Pasteur MSD (SPMSD), and Sanofi in Finland and the United Kingdom. During this time, she held leadership positions spanning clinical research, market access strategies, and commercial operations, including five years as the General Manager and Country Lead for Sanofi Finland.

‍

Alongside her work, Vuola completed post-graduate health economics studies at University of York and a minor in accounting at Aalto University. She also served for eight years as a member of the board of Pharma Industry Finland (Lääketeollisuus ry).

‍

For the past three years, Vuola has worked as an independent consultant for international pharmaceutical companies and for Finnish companies within the health and life science space. She also serves on the board of Pharmatest Services Oy, a provider of preclinical research services.

‍

Vaccines have been at the core of Vuola’s career from the outset. In her new role, she intends to bring together research, commercial operations, and corporate leadership for the long-term success of FVR.

‍